ANIRACETAM

Possibly Marketed Outside US

Details

Stereochemistry	ACHIRAL
Molecular Formula	C12H13NO3
Molecular Weight	219.2365
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

SMILES

COC1=CC=C(C=C1)C(=O)N2CCCC2=O

InChI

InChIKey=ZXNRTKGTQJPIJK-UHFFFAOYSA-N

InChI=1S/C12H13NO3/c1-16-10-6-4-9(5-7-10)12(15)13-8-2-3-11(13)14/h4-7H,2-3,8H2,1H3

HIDE SMILES / InChI

Molecular Formula	C12H13NO3
Molecular Weight	219.2365
Charge	0
Count	MOL RATIO 1 MOL RATIO (average)

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description

Aniracetam is a nootropic drug. It behaves as a positive modulator of AMPA-sensitive glutamate receptors. Aniracetam is clinically used in patients with mild to moderate senile dementia of the Alzheimer type. In Japan, the drug was prescribed for eight years to treat emotional disturbances, such as depressed mood and anxiety/agitation, but not memory impairment following cerebral infarction. Aniracetam (Draganon®) has been withdrawn from the Japanese market because of the unexpected failure in the latest placebo-controlled double-blind study. Animal studies demonstrated that aniracetam has clinical potential in personality disorders, anxiety, depression, posttraumatic stress disorder, attention-deficit/hyperactivity disorder, autism, negative symptoms of schizophrenia, and sleep disorders.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Glutamate receptor ionotropic AMPA 41	Positive Allosteric Modulator 179

Conditions

Condition	Modality	Targets	Highest Phase	Product
Senile dementia of the Alzheimer type 1	Primary		Approved 8,429	AMPAMET

PubMed

Show entries

Title	Date	PubMed
Interactions between oxiracetam, aniracetam and scopolamine on behavior and brain acetylcholine.	1987 Jul	3659072
Aniracetam restores motivation reduced by satiation in a choice reaction task in aged rats.	2001 Jan	11274709
Positive allosteric modulators of AMPA receptors reduce proton-induced receptor desensitization in rat hippocampal neurons.	2001 May	11353019
The AMPA receptor allosteric potentiator PEPA ameliorates post-ischemic memory impairment.	2001 Sep 17	11588608
Negative allosteric modulation of AMPA-preferring receptors by the selective isomer GYKI 53784 (LY303070), a specific non-competitive AMPA antagonist.	2002 Fall	12353057

Showing 1 to 5 of 13 entries

Previous1 2 3Next

Patents

Sample Use Guides

In Vivo Use Guide

1.5 gm daily

Route of Administration: Oral

In Vitro Use Guide

Abeta25-35 (1 microM) largely increased ree calcium concentrations in frontal cortical (FC) and hippocampal (HP) synaptosomes in 3 months old mice, but this effect on HP synaptosomes was effectively reversed by aniracetam (1-4 mM).